{"id":952301,"date":"2026-05-11T09:22:15","date_gmt":"2026-05-11T09:22:15","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/952301\/"},"modified":"2026-05-11T09:22:15","modified_gmt":"2026-05-11T09:22:15","slug":"ozempic-works-best-for-those-triggered-by-sight-and-smells-of-food","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/952301\/","title":{"rendered":"Ozempic works best for those triggered by sight and smells of food"},"content":{"rendered":"

Doctors prescribing drugs<\/a> like Ozempic have gotten very good at anticipating outcomes. <\/p>\n

It\u2019s easy to anticipate that blood sugar will likely come down, and weight will probably drop. <\/p>\n


\n \"EarthSnap\"\/
\n<\/a><\/p>\n

What\u2019s proved much harder to predict is why some patients see dramatic results after a year on the medication, while others on the same drug and same dose see far less.<\/p>\n

A year-long study from Japan suggests the explanation isn\u2019t in the drug at all \u2013 it\u2019s in how the patient overeats.<\/p>\n

A puzzle that\u2019s hard to explain<\/p>\n

Ozempic<\/a>, Wegovy, and Mounjaro have transformed care for many people with type 2 diabetes. <\/p>\n

But the results are uneven. Some patients lose 20 pounds and watch their numbers stabilize. Others see only modest changes after a year on the same medication.<\/p>\n

A team led by Professor Daisuke Yabe of Kyoto University<\/a> and Dr. Takehiro Kato of Gifu University<\/a> followed 92 adults with type 2 diabetes through their first 12 months on these drugs. <\/p>\n

Working across hospitals in Gifu Prefecture, Japan, they wanted to know whether the way a person tends to overeat could predict who would benefit most.<\/p>\n

Drugs change eating behavior<\/p>\n

GLP-1 drugs mimic a hormone the gut releases after meals. They prompt the pancreas to release more insulin and slow how fast the stomach empties. <\/p>\n

They also appear to reduce appetite through signals in the brain \u2013 though exactly how much weight any one person loses from that effect varies considerably.<\/p>\n

Appetite runs on different inputs: the sight of food, the smell of food, the pull of stress or sadness. A drug that quiets one input may leave the others largely untouched.<\/p>\n

Three differing eating patterns<\/p>\n

A validated questionnaire sorted participants by how they tend to overeat. Three patterns emerged.<\/p>\n

The first was external eating \u2013 reaching for food because it looks or smells good, even when not hungry.<\/p>\n

The second was emotional eating<\/a> \u2013 eating to cope with stress, sadness, or boredom. Restrained eating, the third pattern, involved the deliberate effort to limit intake.<\/p>\n

Most people show some mix of all three. The question was whether that mix changed how well the drug worked over a full year.<\/p>\n

A full year of tracking<\/p>\n

Participants started one of four GLP-1 medications \u2013 oral or injectable semaglutide, dulaglutide, or liraglutide. <\/p>\n

Researchers tracked weight, body fat, blood sugar, cholesterol, and dietary intake at the start, at three months, and at 12 months.<\/p>\n

By year\u2019s end, the average participant had lost about 8 pounds and dropped nearly 2 percentage points of body fat. <\/p>\n

Blood <\/a>sugar came down from an HbA1c of 8.2 to 7.0 \u2013 HbA1c being a standard measure of average blood sugar control over several months.<\/p>\n

Muscle mass held steady throughout \u2013 an unusual finding given recurring concerns about muscle loss on these drugs \u2013 and cholesterol numbers improved as well.<\/p>\n

External eating stands out<\/p>\n

At the three-month checkup, all three eating-behavior scores were moving. Emotional eating dropped. Restrained eating ticked up. External eating fell.<\/p>\n

Then the patterns diverged. Emotional eating drifted back to baseline by month 12. Restrained eating did the same. <\/p>\n

But external eating stayed lower for the full year \u2013 against the direction of an earlier report<\/a>.<\/p>\n

Until this study, no one had clearly shown which eating pattern best predicts long-term success on GLP-1 drugs in real clinical practice. <\/p>\n

Higher external eating scores at the start of treatment predicted greater weight loss after 12 months. <\/p>\n

The stronger a person\u2019s pull toward tempting food at the outset, the more weight they tended to lose. Emotional eating showed no such link.<\/p>\n

Connection of brain cues and appetite<\/p>\n

What might explain it? Brain imaging offers a clue. People with higher body mass often show heightened activity in brain areas linked to craving and reward when shown pictures of food. <\/p>\n

A trial<\/a> using a related GLP-1 drug found that this elevated activity appeared to ease during treatment.<\/p>\n

Whether the drug produces this effect directly, or works through other appetite pathways, isn\u2019t fully settled. <\/p>\n

The behavioral pattern is clear either way. External eaters reported less pull toward tempting food, and that change held across 12 months.<\/p>\n

Treatment may need tailoring<\/p>\n

\u201cGLP-1 receptor agonists are effective for individuals who experience weight gain or elevated blood glucose levels due to overeating triggered by external stimuli.\u201d said Yabe.<\/p>\n

\u201cHowever, their effectiveness is less expected in cases where emotional eating is the primary cause,\u201d he continued.<\/p>\n

A separate study<\/a> showed emotional eaters experience less change in food-cue brain activity on GLP-1 therapy, mirroring this paper\u2019s year-long pattern. <\/p>\n

Ask a patient why they tend to overeat, and the answer starts to look like a clinical signal.<\/p>\n

Limitations worth noting<\/p>\n

The 92-person study was observational and relied partly on self-reported eating behavior, which limits how firmly causes can be established. <\/p>\n

Participants came from a single region of Japan, and many appeared highly motivated to improve their health. <\/p>\n

This profile that may not reflect the broader population of people starting these medications.<\/p>\n

Important clinical implications<\/p>\n

Now there\u2019s a clearer answer to why GLP-1 drugs work unevenly. External eating is described as the pull toward food that looks or smells appealing.<\/p>\n

This turned out to be the sharpest predictor of long-term success on these medications.<\/p>\n

The clinical question changes accordingly. It\u2019s no longer simply whether to prescribe Ozempic, but whether to pair it with something more. <\/p>\n

For people who eat because food looks irresistible, the drug carries the load. For people who eat because they are hurting, it\u2019s one piece of a bigger answer.<\/p>\n

The study is published in the journal Frontiers in Clinical Diabetes and Healthcare<\/a>.<\/p>\n

\u2014\u2013<\/p>\n

Like what you read? Subscribe to our newsletter<\/a> for engaging articles, exclusive content, and the latest updates.<\/p>\n

Check us out on EarthSnap<\/a>, a free app brought to you by Eric Ralls<\/a> and Earth.com.<\/p>\n

\u2014\u2013<\/p>\n","protected":false},"excerpt":{"rendered":"Doctors prescribing drugs like Ozempic have gotten very good at anticipating outcomes. It\u2019s easy to anticipate that blood…\n","protected":false},"author":2,"featured_media":952302,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[105,4326,16,15],"class_list":{"0":"post-952301","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-uk","11":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116555216772959890","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/952301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=952301"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/952301\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/952302"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=952301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=952301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=952301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}